SCHEMBL3015041

SCHEMBL3015041

Cc1ccc(F)cc1S(=O)(=O)C1CCN(c2nc(Cc3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 5/20 0.36
MAPK1 P28482 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HRH3 Q9Y5N1 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
CTSS P25774 3/20 0.33
USP30 Q70CQ3 1/20 0.33
KMT2A Q03164 1/20 0.33
AR P10275 1/20 0.33
DNM1L O00429 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011909 0.94 KMT2A (0.35) NAAAMAPK1SMN1; SMN2HRH3NPC1
SCHEMBL3003779 0.94 NAAA (0.35) NAAAMAPK1SMN1; SMN2HRH3NPC1
SCHEMBL3019125 0.93 KMT2A (0.36) NAAAMAPK1SMN1; SMN2HRH3NPC1
SCHEMBL3018837 0.92 NAAA (0.35) NAAAMAPK1SMN1; SMN2HRH3NPC1
SCHEMBL3011191 0.92 NAAA (0.36) NAAAMAPK1SMN1; SMN2HRH3NPC1
SCHEMBL3016809 0.92 NAAA (0.40) NAAAMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL3019028 0.91 NAAA (0.36) NAAAMAPK1SMN1; SMN2HRH3NPC1
SCHEMBL3016341 0.90 MAPT (0.38) NAAASMN1; SMN2HRH3RAB9AAR
SCHEMBL3012974 0.90 MAPT (0.38) NAAAMAPK1SMN1; SMN2CTSSKMT2A
SCHEMBL3009006 0.90 SMN1; SMN2 (0.37) NAAAMAPK1SMN1; SMN2HRH3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA NAAA 3229/4885MAPK1 2767/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.